{
    "id": 7559,
    "fullName": "TSC2 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TSC2 loss indicates loss of the TSC2 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7249,
        "geneSymbol": "TSC2",
        "terms": [
            "TSC2",
            "LAM",
            "PPP1R160",
            "TSC4"
        ]
    },
    "variant": "loss",
    "createDate": "06/11/2015",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9372,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Rapamune (sirolimus) and Buthionine sulfoximine (BSO) resulted in increased production of ROS and cell death in transformed cells deficient for TSC2 in culture, and apoptotic activity and tumor regression in ELT3 cell line xenograft models also deficient for TSC2 (PMID: 27197195).",
            "molecularProfile": {
                "id": 7439,
                "profileName": "TSC2 loss"
            },
            "therapy": {
                "id": 4990,
                "therapyName": "Buthionine sulfoximine + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7134,
                    "pubMedId": 27197195,
                    "title": "mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27197195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7439,
            "profileName": "TSC2 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 5298,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "TSC2 loss"
                },
                {
                    "id": 5297,
                    "name": "mTOR Inhibitor",
                    "profileName": "TSC2 loss"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}